Abstract
The purpose of this review is to describe the potential sources of variability or discrepancy in interpretation of cystic renal masses under the Bosniak v2019 classification system. Strategies to avoid these pitfalls and clinical examples of diagnostic approaches are also presented. Potential pitfalls in the application of Bosniak v2019 are divided into three categories: interpretative, technical, and mass related. An organized, comprehensive review of possible discrepancies in interpreting Bosniak v2019 cystic masses is presented with pictorial examples of difficult clinical cases and proposed solutions. The scheme provided can guide readers to consistent, precise application of the classification system. Radiologists should be aware of the possible sources of misinterpretation of cystic renal masses when applying Bosniak v2019. Knowing which features and types of cystic masses are prone to interpretive errors, in addition to the inherent trade-offs between the CT and MR techniques used to characterize them, can help radiologists avoid these pitfalls.
Similar content being viewed by others
References
Silverman SG, Pedrosa I, Ellis JH, et al. Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology 2019; 292:475–488
Davies L, Petitti DB, Woo M, Lin JS. Defining, Estimating, and Communicating Overdiagnosis in Cancer Screening. Ann Intern Med 2018; 169:739
Esserman LJ, Thompson IM, Jr., Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 2013; 310:797–798
Tse JR, Shen J, Shen L, Yoon L, Kamaya A. Bosniak Classification of Cystic Renal Masses Version 2019: Comparison of Categorization using CT and MRI. AJR American Journal of Roentgenology 2020;
Tse JR, Shen J, Yoon L, Kamaya A. Bosniak Classification Version 2019 of Cystic Renal Masses Assessed With MRI. AJR American journal of roentgenology 2020; 215:413–419
Bai X, Sun SM, Xu W, et al. MRI-based Bosniak Classification of Cystic Renal Masses, Version 2019: Interobserver Agreement, Impact of Readers’ Experience, and Diagnostic Performance. Radiology 2020:200478
Bosniak MA, Rofsky NM. Problems in the detection and characterization of small renal masses. Radiology 1996; 200:286–287
Israel GM, Bosniak MA. Pitfalls in renal mass evaluation and how to avoid them. Radiographics 2008; 28:1325-1338
Society of Abdominal Radiology Renal Cell Carcinoma Disease Focused Panel.
Jonisch AI, Rubinowitz AN, Mutalik PG, Israel GM. Can high-attenuation renal cysts be differentiated from renal cell carcinoma at unenhanced CT? Radiology 2007; 243:445–450
Leao LRS, Mussi TC, Yamauchi FI, Baroni RH. Common pitfalls in renal mass evaluation: a practical guide. Radiol Bras 2019; 52:254–261
Ho VB, Allen SF, Hood MN, Choyke PL. Renal masses: quantitative assessment of enhancement with dynamic MR imaging. Radiology 2002; 224:695–700
Birnbaum BA, Maki DD, Chakraborty DP, Jacobs JE, Babb JS. Renal cyst pseudoenhancement: evaluation with an anthropomorphic body CT phantom. Radiology 2002; 225:83–90
Maki DD, Birnbaum BA, Chakraborty DP, Jacobs JE, Carvalho BM, Herman GT. Renal cyst pseudoenhancement: beam-hardening effects on CT numbers. Radiology 1999; 213:468–472
Patel J, Davenport MS, Khalatbari S, Cohan RH, Ellis JH, Platt JF. In vivo predictors of renal cyst pseudoenhancement at 120 kVp. AJR American Journal of Roentgenology 2014; 202:336–342
Hindman NM. Approach to Very Small (< 1.5 cm) Cystic Renal Lesions: Ignore, Observe, or Treat? AJR American Journal of Roentgenology 2015; 204:1182–1189
Tu W, Alzahrani A, Currin S, et al. Evaluation of a free-breathing respiratory-triggered (Navigator) 3-D T1-weighted (T1W) gradient recalled echo sequence (LAVA) for detection of enhancement in cystic and solid renal masses. Eur Radiol 2019; 29:2507–2517
Israel GM, Hindman N, Bosniak MA. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology 2004; 231:365–371
Zhong J, Cao F, Guan X, Chen J, Ding Z, Zhang M. Renal cyst masses (Bosniak category II-III) may be over evaluated by the Bosniak criteria based on MR findings. Medicine (Baltimore) 2017; 96:e9361
Weibl P, Klatte T, Kollarik B, et al. Interpersonal variability and present diagnostic dilemmas in Bosniak classification system. Scand J Urol Nephrol 2011; 45:239–244
Krishna S, Murray CA, McInnes MD, et al. CT imaging of solid renal masses: pitfalls and solutions. Clin Radiol 2017; 72:708–721
McGahan JP, Sidhar K, Fananapazir G, et al. Renal cell carcinoma attenuation values on unenhanced CT: importance of multiple, small region-of-interest measurements. Abdom Radiol (NY) 2017; 42:2325–2333
Padole A, Ali Khawaja RD, Kalra MK, Singh S. CT radiation dose and iterative reconstruction techniques. AJR American Journal of Roentgenology 2015; 204:W384–392
Geyer LL, Schoepf UJ, Meinel FG, et al. State of the Art: Iterative CT Reconstruction Techniques. Radiology 2015; 276:339–357
Silverman SG, Israel GM, Herts BR, Richie JP. Management of the incidental renal mass. Radiology 2008; 249:16–31
Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology 2005; 236:441–450
Sahni VA, Silverman SG. Imaging management of incidentally detected small renal masses. Semin Intervent Radiol 2014; 31:9–19
Adey GS, Pedrosa I, Rofsky NM, Sanda MG, DeWolf WC. Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms. Urology 2008; 71:47–51
Udare A, Abreu-Gomez J, Krishna S, McInnes M, Siegelman E, Schieda N. Imaging Manifestations of Acute and Chronic Renal Infection That Mimics Malignancy: How to Make the Diagnosis Using Computed Tomography and Magnetic Resonance Imaging. Can Assoc Radiol J 2019; 70:424–433
Andrew B. Rosenkrantz BWM, Elie Portnoy, Jonathan Melamed, Samir S.Taneja, Natasha E.Wehrlia. Impact of size of region-of-interest on differentiation of renal cell carcinoma and renal cysts on multi-phase CT: Preliminary findings. European Journal of Radiology 2014; 83:239–244
Mullett R, Belfield JC, Vinjamuri S. Calyceal diverticulum - a mimic of different pathologies on multiple imaging modalities. J Radiol Case Rep 2012; 6:10–17
O’Connor SD, Pickhardt PJ, Kim DH, Oliva MR, Silverman SG. Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management. AJR American journal of roentgenology 2011; 197:139–145
Pooler BD, Pickhardt PJ, O’Connor SD, Bruce RJ, Patel SR, Nakada SY. Renal cell carcinoma: attenuation values on unenhanced CT. AJR American Journal of Roentgenology 2012; 198:1115–1120
Schieda N, Vakili M, Dilauro M, Hodgdon T, Flood TA, Shabana WM. Solid Renal Cell Carcinoma Measuring Water Attenuation (-10 to 20 HU) on Unenhanced CT. AJR American journal of roentgenology 2015; 205:1215–1221
Kim NY, Lubner MG, Nystrom JT, et al. Utility of CT Texture Analysis in Differentiating Low-Attenuation Renal Cell Carcinoma From Cysts: A Bi-Institutional Retrospective Study. AJR American journal of roentgenology 2019; 213:1259–1266
Webster WS, Thompson RH, Cheville JC, Lohse CM, Blute ML, Leibovich BC. Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma. Urology 2007; 70:900–904; discussion 904
Park SY, Shin SJ, Cho NH, et al. Solid Small Renal Mass Without Gross Fat: CT Criteria for Achieving Excellent Positive Predictive Value for Renal Cell Carcinoma. AJR American journal of roentgenology 2018; 210:W148–W155
Hartman DS, Davis CJ, Jr., Johns T, Goldman SM. Cystic renal cell carcinoma. Urology 1986; 28:145–153
Oliva MR, Glickman JN, Zou KH, et al. Renal cell carcinoma: t1 and t2 signal intensity characteristics of papillary and clear cell types correlated with pathology. AJR American journal of roentgenology 2009; 192:1524–1530
Adams LC, Bressem KK, Jurmeister P, et al. Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results. Cancer Imaging 2019; 19:35
Cornelis F, Helenon O, Correas JM, et al. Tubulocystic renal cell carcinoma: a new radiological entity. Eur Radiol 2016; 26:1108–1115
Mnatzakanian GN, Shinagare AB, Sahni VA, Hirsch MS, Silverman SG. Early-stage clear cell tubulopapillary renal cell carcinoma: imaging features and distinction from clear cell and papillary subtypes. Abdom Radiol (NY) 2016; 41:2187–2195
Cheon PM, Rebello R, Naqvi A, Popovic S, Bonert M, Kapoor A. Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic. Curr Oncol 2018; 25:e220–e223
Paschall AK, Nikpanah M, Farhadi F, et al. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. Clin Imaging 2020; 68:14–19
Kim E, Zschiedrich S. Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. Front Pediatr 2018; 6:16
Ristau BT, Kamat SN, Tarin TV. Abnormal Cystic Tumor in a Patient with Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome: Evidence of a Precursor Lesion? Case Rep Urol 2015; 2015:303872
Wang SS, Gu YF, Wolff N, et al. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci U S A 2014; 111:16538–16543
Chahoud J, McGettigan M, Parikh N, et al. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol 2020;
Hyder A Omer MRH. Primary Renal Lymphoma. Nephrology 2007; 12:314–315
Natalya Hakim M, Yevgen Chornenkyy, Shadi Qasem. Malignant Perivascular Epithelioid Cell Tumor Mimicking Renal Cell Carcinoma: A Diagnostic Pitfall. American Journal of Clinical Pathology 2019; 152:S62
Cyriac S RR, Shirley S, Sagar GT. Primary renal lymphoma mimicking renal cell carcinoma. Indian J Urol 2010; 26:441–443
Funding
This work was partially supported by NIH Grant R01CA154475 (IP).
Author information
Authors and Affiliations
Contributions
EE, NC, SK, NS and IP performed the literature search and drafted the manuscript. MSD, NH, SS, and IP critically revised the manuscript and contributed case examples.
Corresponding author
Ethics declarations
Conflict of interest
Matthew S. Davenport receives royalties from Wolters Kluwer and uptodate.com. Ivan Pedrosa received an honorarium from Bayer Healthcare and has received stock options from Health Tech International. He also has institutional research agreements with Philips Healthcare and with Siemens Healthcare. Ivan Pedrosa serves on the Scientific Advisory Board for Bayer Healthcare and is a Scientific Advisor for Health Tech International. He has also been a Co-inventor of patents (no royalties received) for Philips Healthcare. Other authors have no disclosures.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Edney, E., Davenport, M.S., Curci, N. et al. Bosniak classification of cystic renal masses, version 2019: interpretation pitfalls and recommendations to avoid misclassification. Abdom Radiol 46, 2699–2711 (2021). https://doi.org/10.1007/s00261-020-02906-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-020-02906-8